Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 9/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7038063 | 0.77 | HTR2A (0.42) | DRD2HTR1AHTR2AHTR2CHTR2B | |
| SCHEMBL6323565 | 0.77 | DRD2 (0.41) | DRD2DRD4DRD3HTR1AHTR2A | |
| SCHEMBL6864820 | 0.76 | DRD4 (0.45) | DRD2DRD4DRD3HTR1APOLB | |
| SCHEMBL7038637 | 0.76 | HTR1A (0.49) | DRD2DRD4DRD3HTR1ASLC6A4 | |
| SCHEMBL6202828 | 0.71 | HTR1A (0.65) | DRD2HTR1AHTR2APOLBSLC6A4 | |
| SCHEMBL6202240 | 0.70 | HTR1A (0.54) | DRD2DRD4DRD3HTR1AHTR2A | |
| SCHEMBL6864588 | 0.69 | DRD2 (0.70) | DRD2DRD4DRD3HTR1AHTR2A | |
| SCHEMBL6200972 | 0.69 | HTR1A (0.55) | DRD2HTR1AHTR2ASLC6A4 | |
| SCHEMBL6202163 | 0.69 | HTR1A (0.53) | DRD2DRD4DRD3HTR1AHTR2A | |
| SCHEMBL6864825 | 0.68 | DRD2 (0.41) | DRD2DRD4DRD3POLBGNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803368-B2 | FOR THERAPY OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, BIPOLAR DISORDER, PARKINSON'S DISEASE, L-DOPA INDUCED PSYCHOSES OR DYSKINESIAS, TOURETTE'S SYNDROME, HYPERPROLACTINEMIA, OR ADDICTION TO ETHANOL, NICOTINE, COCAINE | WYETH | 2004-10-12 | — | — | US | claimed |
| US-20020183330-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[a]naphthalene | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-05 | — | — | US | claimed |
| WO-2002085912-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-6,9-DIOXA-1,3-DIAZA-CYCLOPENTA[a]NAPHTHALENE | WYETH (US) | 2002-10-31 | — | — | WO | claimed |
| US-6803368-B2 | FOR THERAPY OF SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER, BIPOLAR DISORDER, PARKINSON'S DISEASE, L-DOPA INDUCED PSYCHOSES OR DYSKINESIAS, TOURETTE'S SYNDROME, HYPERPROLACTINEMIA, OR ADDICTION TO ETHANOL, NICOTINE, COCAINE | WYETH | 2004-10-12 | — | — | US | disclosed |
| US-20020183330-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[a]naphthalene | AMERICAN HOME PRODUCTS CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2002085912-A1 | ANTIPSYCHOTIC AMINOMETHYL DERIVATIVES OF 7,8-DIHYDRO-3H-6,9-DIOXA-1,3-DIAZA-CYCLOPENTA[a]NAPHTHALENE | WYETH (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183330-A1 | Antipsychotic aminomethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diaza-cyclopenta[a]naphthalene | SNCA, PARK7, SYNJ1 | DRD2 17/4885DRD4 41/4885DRD3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.